ScreenerHero

MPLT MapLight Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · maplightrx.com
9.360USD-3.41%Mkt Cap: 520.19M $P/E: —

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap520.19M USD
Enterprise Value146.66M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-161.15M USD
Revenue/Share—
Last Price9.360 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees133
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.83
PEG—
EV/EBITDA-0.60
EV/Revenue—
P/S—
P/B1.26
EPS (TTM)-6.53
EPS (Forward)-3.42
52W Range
8.9201% of range40.43
52W High40.43 USD
52W Low8.920 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-35.16%
ROA-33.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.14M USD
CapEx (TTM)473.00K USD
FCF Margin—
FCF Yield-18.30%
Net Debt-302.74M USD
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity0.01
Current Ratio16.52
Quick Ratio15.79
Book Value/Sh7.67 USD
Cash/Share6.57 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)26.54 USD
Upside (mean)+183.5%
Target Range13.00 USD – 43.00 USD
13.00+183.5% to mean43.00
# Analysts13
Ownership
Shares Out.52.85M
Float16.05M
Insiders52.28%
Institutions48.65%
Short Interest
Short Ratio5.6d
Short % Float10.23%
Short % Out.5.93%
Shares Short3.30M
Short (prev mo.)3.24M
Technical
SMA 5011.99 (-21.9%)
SMA 20021.45 (-56.4%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)544.24K
Avg Vol (10d)383.27K
Technical Indicators
RSI (14)29.0
MACD-1.1870
MACD Signal-1.2349
MACD Hist.+0.0479
BB Upper13.43 USD
BB Middle10.90 USD
BB Lower8.370 USD
BB Width46.40%
ATR (14)0.8487 USD
Vol Ratio (20d)0.54x